|
[ Supplements Archive ] [ Main Archives Page ] [ Glossary/Index ] [ FAQ ] [ Recommended Books ] [ Bulletin Board ] |
Search this site! | |
I found an article on pyridoxine which is extremenly disturbing (Dalton & Dalton, Acta Neurol Scand, 76:8-11, 1987). It is somewhat difficult to interpret, but I shall try to distill it down to some of its main points (at least as I interpret them). 241 Women received approximately 116 mg pyridoxine daily (mean value) over an extended period of time. Contrary to the usual meaning of the use of the phrase "control group," the authors define the control groups as those women who did not exhibit neurotoxicity. Of these 241 women, 43 % (103/241, expressed as a percentage) exhibited neurotoxicity (calculated from Table 1). Please note that Table 1 is confusing, since it appears that "Controls" did not experience toxicity, despite the table heading "Women with neurological symptoms of B6 overdosage." For controls, it apparently just lists dosing information. Table 1 indicates it takes more than 6 months of dosing to exhibit neurotoxicity. Also derived from Table 1, it appears that of those 103 women who exhibited neurotoxicity, 21 % were taking doses of less than 50 mg daily (0.20 x 103 x 100).
It is somewhat difficult to interpret, but I shall try to distill it down to some of its main points (at least as I interpret them). 241 Women received approximately 116 mg pyridoxine daily (mean value) over an extended period of time. Contrary to the usual meaning of the use of the phrase "control group," the authors define the control groups as those women who did not exhibit neurotoxicity. Of these 241 women, 43 % (103/241, expressed as a percentage) exhibited neurotoxicity (calculated from Table 1). Please note that Table 1 is confusing, since it appears that "Controls" did not experience toxicity, despite the table heading "Women with neurological symptoms of B6 overdosage." For controls, it apparently just lists dosing information. Table 1 indicates it takes more than 6 months of dosing to exhibit neurotoxicity. Also derived from Table 1, it appears that of those 103 women who exhibited neurotoxicity, 21 % were taking doses of less than 50 mg daily (0.20 x 103 x 100).